Patent Grant
9539332
Field of the Invention
This invention generally relates to a plasticizer for coating compositions for coating an implantable device such as a drug-delivery stent.
Description of the Background
Degradable polymers have found numerous medical applications. One of these applications is to serve as a coating material for stents. However, articles formed of these biodegradable polymers may have undesirable properties, e.g., lack of flexibility, low elongation, too low a drug permeability, or poor processability. One of the commonly used methods to circumvent these shortcomings is to use a plasticizer.
Some most commonly used plasticizers are petrochemicals such as phthalates. Another commonly used plasticizer is epoxided vegetable oil. Some other materials such as small organic molecules, or inorganic materials, such as phosphoric acid can be used as plasticizers. However, many of these plasticizers either lack biocompatibility or have other undesirable properties. For example, petrochemical plasticizers such as phthalates are often toxic chemicals, and epoxided vegetable oil at higher levels may not mix properly into the plastics formulation or may cause plastics formulations to become brittle. Small organic molecules can also be toxic. In addition, they may have high vapor pressures, which may cause them to diffuse out of an article containing such a plasticizer and create shelflife stability issues because the mechanical integrity and the drug release rate, in the case of coating on a drug-delivery stent, will change over time.
Therefore, there is a need for plasticizers for use in coating compositions for coating a medical device such as a drug-delivery stent.
The compositions and the coatings formed thereof disclosed herein address the above described problems and needs.
Provided herein is a plasticizer that can be used with a biocompatible polymeric material to form a coating composition for coating an implantable device such a stent. The plasticizer is biocompatible and non-volatile. The biocompatible polymeric material can be a biodegradable or non-biodegradable polymer. The coating composition can optionally include at least one bioactive agent.
The implantable device can be a stent that can be a metallic, biodegradable or nondegradable stent. The stent can be intended for neurovasculature, carotid, coronary, pulmonary, aorta, renal, biliary, iliac, femoral, popliteal, or other peripheral vasculature. The implantable device may be used to prevent or treat a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
Provided herein is a plasticizer that can be used with a biocompatible polymeric material to form a coating composition for coating an implantable device such a stent. In some embodiments, for example, stents made from a biodegradable material, the plasticizer can be included in the material from which the stent is made. The plasticizer is biocompatible and non-volatile. The biocompatible polymeric material can be a biodegradable or non-biodegradable polymer. The polymer can also be bioabsorbable or non-absorbable. The coating composition can optionally include at least one bioactive agent and/or biobeneficial material.
The implantable device can be a stent that can be a metallic, biodegradable or nondegradable stent. The stent can be intended for neurovasculature, carotid, coronary, pulmonary, aorta, renal, biliary, iliac, femoral, popliteal, or other peripheral vasculature. The stent can be used to treat or prevent a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
The plasticizer described herein can be any chemical compound capable altering the coating mechanical properties, such as by altering, e.g., lowering, the glass transition temperature of the polymer. By doing so, certain desirable mechanical properties such as flexibility and elongation are imparted to the coating. In general, the plasticizer has no vapor pressure so it cannot diffuse via a vapor phase into other phases or components in the final package of an implantable device on which the coating includes the plasticizer. Migration of the plasticizer by contact, through diffusion, can be controlled by using very impermeable, protective sheaths. The plasticizer is compatible with the polymeric material such as poly(D,L-lactide) and plasticizes the polymeric material. In addition, when used in a drug-delivery coating, the plasticizer does not substantially, or significantly, affect the drug stability. Altering the drug release kinetics is possible, if desired, particularly by selection of the type and quantity of plasticizing compound. The plasticizer can be made to change the degradation rate of the polymer if desirable.
In general, the plasticizer can exist in any percentage capable of plasticizing the coating composition. An exemplary range of the plasticizer is 0.1% to 40% by weight of the coating composition. Another representative range of the plasticizer range is 1% to 20% by weight of the coating composition.
The following describes several embodiments of the plasticizer described herein.
A. Low Molecular Weight Oligomers of Monomers Forming a Biodegradable Polymer
In one embodiment, the plasticizer can be low molecular weight oligomers of monomers forming a biodegradable polymer. For example, the oligomer can be a dimer, trimer, tetramers or oligomers of lactic acid, which forms PDLL or poly(D,L-lactic acid) (PDLLA). The low molecular weight oligomer can be a cyclic oligomer or a linear oligomer. In some embodiments, the plasticizer has the structure of formula I:
In some other embodiments, the plasticizer has the structure of formula II:
R1, R2, n and m of formula I and R1, n and m of formula II are defined as follows:
Preferred plasticizers will have molecular weights less than 10,000 daltons.
Some exemplary plasticizers of formulae I or II are cyclic or linear oligomers of glycolic acid, L-lactic acid, D-lactic acid, D,L-lactic acid, 3-hydroxypropanoic acid, 3-hydroxybutyric acid, 4-hydroxybutyric acid, 3-hydroxyvalerate, 4-hydroxyvalerate, 5-hydroxyvalerate, 3-hydroxyhexanoate, 4-hydroxyhexanoate, 5-hydroxyhexanoate, ε-caprolactone, 6-hydroxycaproic acid, γ-butyrolactone, β-butyrolactone and combinations thereof. Some other exemplary plasticizer of formula I can be dimer, trimer of lactic acid. In one embodiment, the plasticizer is an oligomer of poly(D,L-lactic acid) (PDLLA) having a molecular weight in the range from 1000 Daltons to 5,000 Daltons.
The low molecular weight oligomers described herein, for example plasticizers of formulae I or II, can be formed by methods documented in the art (see, for example, see, for example, Michael Smith, Organic Synthesis, 2nd Edition, McGraw-Hill, 2001). In one embodiment, the oligomer can be formed by controlled hydrolysis of a biodegradable polymer. For example, oligomers of 3-hydroxybutyric acid or polylactide can be formed by hydrolyzing poly(3-hydroxybutyric acid) (see, for example, Seebach, et al., Organic Syntheses, CV 9: 483; Tsuji and Nakahara, J. Appl. Polymer Science, 88(1):186-194 (2002)). Cyclic oligomers, for example cyclic oligomers of poly(ethylene terephthalate), can be formed by cyclization of short-chain linear oligomers, cyclodepolymerization from chain ends of a polymer, or ester-interchange reaction occurring randomly within or between polymer chains of a polymer (see, e.g., Cho, et al., Macromol. Chem. Phys. 202:998-1003 (2001)). Scheme 1 shows formation of a lactic acid trimer (Scheme I):
The plasticizer of formula I, produced by scheme I, has a terminal carboxy group. This may affect the stability of a drug in a drug-delivery coating that includes the plasticizer under in vivo conditions. For example, everolimus has a lactone functionality. The existence of a free acid end group in a plasticizer in a drug-delivery coating containing everolimus may cause the lactone group in everolimus to undergo the hydrolytic reaction. A free acid end group can be avoided by either using a different initiator in the plasticizer synthesis or by esterifying the acid endgroup. One example of using a different initiator in the ring opening synthesis, which yields an ester endgroup, is shown in Scheme II.
B. Fatty Acids
In another embodiment, the plasticizer can be a fatty acid. The fatty acid can be synthetic or naturally occurring fatty acids. Some fatty acids are endogenous compounds. The fatty acids may be saturated or unsaturated. The fatty acid can be liquid or solid, preferably liquid fatty acids. Representative natural fatty acids include, but are not limited to, palmitoleic acid, lauric acid, oleic acid, linoleic acid, and arachidonic acid. Representative synthetic fatty acids include, for example, C6-C15 alkanoic acids such as hexanoic acid, heptanoic acid, or octanoic acid.
C. Fatty Acid Esters
In a further embodiment of the present invention, the plasticizer described herein can be esters of the fatty acids. The ester can be made to be miscible with the polymer forming the coating on an implantable device by selecting a hydrocarbon chain, e.g., an alkyl chain, to form the ester group. The term “miscible” as used herein means the ester has a substantial solubility in the polymer. Fatty acid esters would not influence the polymer degradation kinetics of the coating polymer or stability of the drug in a drug-delivery coating. For example, useful plasticizers can be the ethyl, propyl, or butyl ester of oleic acid, which are all commercially available.
D. Glycerides
In a further embodiment, the plasticizers can be a glyceride. The glyceride can be a mono, di, or triglyceride. Triglycerides are already present in the blood stream. The glycerides can be natural glycerides or synthetic glycerides and can contain any of the fatty acids described above. For example, most naturally occurring triglycerides contain stearate, palmitate, linoleic, oleic fatty acid, or a mixture thereof.
E. Fatty Alcohols
In still a further embodiment, the plasticizer can be a fatty alcohol. The fatty alcohol can be synthetic or naturally occurring fatty alcohols. Some representative fatty alcohols include, but are not limited to, fatty alcohols described in the FDA GRAS (generally recognized as safe) list.
E. Other Plasticizers
The plasticizer described herein can be any other materials that are biocompatible and compatible with the coating polymer. For example, citric acid esters have been studied as plasticizers for poly(L-lactide) (Scapin, S M N, et al., J. Mater. Sci.: Mater. In Med. 14:635-640 (2003)). Some other plasticizers that may be useful include, for example, the plasticizers described in U.S. Pat. Nos. 4,399,248; 4,426,542; 4,938,971; 5,189,105; 4,857,573; 5,248,531; and 5,688,850.
In some embodiments, the plasticizer described herein can be, for example, L-lactic acid, D-lactic acid or D,L-lactic acid monomer, a lactic acid derivative such as ethyl lactate, a polyalkylene glycol such as polyethylene glycol (PEG) or a polyalkylene oxide or combinations thereof. Ethyl lactide has a relatively low boiling point of 154° C. It can move via vapor in the package on storage, but a lactide of a higher alkyl group such as propyl lactide or butyl lactide have a higher boiling point. PEG is very hydrophilic and will tend to increase the drug release rate by increased water swelling, but this can be offset by lowering the drug/polymer ratio. In some other embodiments, the plasticizer can also be one of biocompatible esters, glycolic acid, 3-hydroxypropanoic acid, 3-hydroxybutyric acid, 4-hydroxybutyric acid, 3-hydroxyvalerate, 4-hydroxyvalerate, 5-hydroxyvalerate, 3-hydroxyhexanoate, 4-hydroxyhexanoate, 5-hydroxyhexanoate, ε-caprolactone, 6-hydroxycaproic acid, γ-butyrolactone, β-butyrolactone or combinations thereof.
Another class of useful plasticizers can be a bioactive molecule or an oligomer thereof capable of plasticizing a coating composition. One of such plasticizers can be aspirin, oligomeric aspirin, the bioactive agents defined below, e.g., everolimus, or pimecrolimus.
A further class of plasticizers can be a low molecular weight polymer having a molecular weight, e.g., below 10,000 Daltons. In some embodiments, the plasticizer can be a hydrophilic material, derivatized hydrophilic material, hydrophobic material, or derivatized hydrophobic material. In some embodiments, the hydrophilic material can be a hydrophilic polymer such as poly(ethylene glycol) (PEG), polyvinylpyrrolidone (PVP), poly(vinyl alcohol) (PVA), polyacrylamide (PAAm), mannose-6-phosphate, quaternary silanes, or combinations thereof. The hydrophobic material can be the biocompatible polymer described below with low molecular weight, some examples of which are low molecular weight poly(ester amide), low molecular weight polyglycerol sebacic acid, and low molecular with triblock poly(D,L-lactic acid)-co-poly(ethylene glycol)-co-poly(D,L-lactic acid) (PDLLA-PEG-PDLLA). Low molecular weight generally means a molecular weight below, e.g., 10,000 Daltons. The low molecular hydrophobic polymer can be modified or derivatized using, e.g., a bioactive agent defined below, one of which is RGD. An exemplary modified or derivatized low molecular weight hydrophobic material is RGD modified poly(D,L-lactic acid).
The biocompatible polymer useful for forming a coating composition with the plasticizers described herein can be any biocompatible polymer known in the art, which can be biodegradable or nondegradable. Biodegradable is intended to include bioabsorbable or bioerodable. Representative examples of polymers that can be used to coat an implantable device in accordance with the present invention include, but are not limited to, poly(ester amide), ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name EVAL), poly(L-lactide), poly(D-lactide), poly(D,L-lactide), poly(D,L-lactide-co-L-lactide), poly(L-lactide-co-glycolide), poly(D,L-lactide-co-glycolide) (PDLLAGA), poly(L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone), poly(hydroxyvalerate), polycaprolactone, poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), polycyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), polyurethanes, polyphosphazenes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers, vinyl halide polymers and copolymers, such as polyvinyl chloride, polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, fluoro polymers or copolymers under the trade name Solef™ or Kynar™ such as polyvinylidene fluoride (PVDF) and poly(vinylidene fluoride-co-hexafluoropropylene), polyvinylidene chloride, poly(butyl methacrylate), polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics, such as polystyrene, polyvinyl esters, such as polyvinyl acetate, copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers, polyamides, such as Nylon 66 and polycaprolactam, alkyd resins, polycarbonates, polyoxymethylenes, polyimides, polyethers, polyvinylpyrrolidone (PVP), poly(vinyl alcohol) (PVA), polyacrylamide (PAAm), poly(glyceryl sebacate), poly(propylene fumarate), epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethyl cellulose.
The biocompatible polymer can provide a controlled release of a bioactive agent, if included in the coating and/or binding the bioactive agent to a substrate, which can be the surface of an implantable device or a coating thereon. Controlled release and delivery of bioactive agent using a polymeric carrier has been extensively researched in the past several decades (see, for example, Mathiowitz, Ed., Encyclopedia of Controlled Drug Delivery, C.H.I.P.S., 1999). For example, PLA based drug delivery systems have provided controlled release of many therapeutic drugs with various degrees of success (see, for example, U.S. Pat. No. 5,581,387 to Labrie, et al.). The release rate of the bioactive agent can be controlled by, for example, by selection of a particular type of biocompatible polymer which can provide a desired release profile of the bioactive agent. The release profile of the bioactive agent can be further controlled by the molecular weight of the biocompatible polymer and/or the ratio of the biocompatible polymer over the bioactive agent. In the case of a biodegradable polymer, the release profile can also be controlled by the degradation rate of the biodegradable polymer. One of ordinary skill in the art can readily select a carrier system using a biocompatible polymer to provide a controlled release of the bioactive agent.
A preferred biocompatible polymer is a polyester, such as one of poly(ester amide), poly(D,L-lactide) (PDLLA), poly(D,L-lactic acid-co-glycolic acid) (PDLLGA), polyglycolic acid (PGA), polyhydroxyalkanoate (PHA), poly(3-hydroxybutyrate) (PHB), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), poly((3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanoate), poly(D,L-lactide), poly(L-lactide), polycaprolactone (PCL) and a combination thereof.
The coating containing the plasticizer described herein may further include a biobeneficial material. The biobeneficial material can be a polymeric material or non-polymeric material. The biobeneficial material is preferably flexible when present as a discrete layer, or confers elastic properties in a blend or copolymer, and is biocompatible and/or biodegradable, more preferably non-toxic, non-antigenic and non-immunogenic. A biobeneficial material is one which enhances the biocompatibility of a device by being non-fouling, hemocompatible, actively non-thrombogenic, or anti-inflammatory, all without depending on the release of a pharmaceutically active agent. As used herein, the term non-fouling is defined as preventing, delaying or reducing the amount of formation of protein build-up caused by the body's reaction to foreign material and can be used interchangeably with the term “anti-fouling.”
Representative biobeneficial materials include, but are not limited to, polyethers such as poly(ethylene glycol), copoly(ether-esters) (e.g. PEO/PLA); polyalkylene oxides such as poly(ethylene oxide), polypropylene oxide), poly(ether ester), polyalkylene oxalates, polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers such as hydroxyethyl methacrylate (HEMA), hydroxypropyl methacrylate (HPMA), hydroxypropyl methacrylamide, PEG acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and n-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA), polystyrene-polyisoprene-polystyrene-co-PEG (SIS-PEG), polystyrene-PEG, polyisobutylene-PEG, polycaprolactone-PEG (PCL-PEG), PLA-PEG, poly(methyl methacrylate)-PEG (PMMA-PEG), polydimethylsiloxane-co-PEG (PDMS-PEG), poly(vinylidene fluoride)-PEG (PVDF-PEG), PLURONIC™ surfactants (polypropylene oxide-co-polyethylene glycol), poly(tetramethylene glycol), hydroxy functional poly(vinyl pyrrolidone), biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen, dextran, dextrin, hyaluronic acid, fragments and derivatives of hyaluronic acid, heparin, fragments and derivatives of heparin, glycosamino glycan (GAG), GAG derivatives, polysaccharide, elastin, chitosan, alginate, silicones, and combinations thereof. In some embodiments, the polymer can exclude any one of the aforementioned polymers.
In a preferred embodiment, the biobeneficial material is a block copolymer comprising flexible poly(ethylene glycol terephthalate)/poly(butylenes terephthalate) (PEGT/PBT) segments (PolyActive™). These segments are biocompatible, non-toxic, non-antigenic and non-immunogenic. Previous studies have shown that the PolyActive™ top coat decreases the thrombosis and embolism formation on stents. PolyActive™ is generally expressed in the form of xPEGTyPBTz, in which x is the molecular weight of PEG, y is percentage of PEGT, and z is the percentage of PBT. A specific PolyActive™ polymer can have various ratios of the PEG, ranging from about 1% to about 99%, e.g., about 10% to about 90%, about 20% to about 80%, about 30% to about 70%, about 40% to about 60% PEG. The PEG for forming PolyActive™ can have a molecular weight ranging from about 300 Daltons to about 100,000 Daltons, e.g., about 300 Daltons, about 500 Daltons, about 1,000 Daltons, about 5,000 Daltons, about 10,000 Daltons, about 20,000 Daltons, or about 50,000 Daltons.
In another preferred embodiment, the biobeneficial material can be a polyether such as polyethylene glycol (PEG) or polyalkylene oxide.
The plasticizers described herein can be used to form a coating on an implantable device with a polymeric material and optionally with one or more bioactive agents. Examples of such agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities. Nucleic acid sequences include genes, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes. Other examples of drugs include antibodies, receptor ligands, and enzymes, adhesion peptides, oligosaccharides, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy. Such agents can also include a prohealing drug that imparts a benign neointimal response characterized by controlled proliferation of smooth muscle cells and controlled deposition of extracellular matrix with complete luminal coverage by phenotypically functional (similar to uninjured, healthy intima) and morphologically normal (similar to uninjured, healthy intima) endothelial cells. Such agents can also fall under the genus of antineoplastic, cytostatic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimitotics include paclitaxel (e.g. TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g. Taxotere®, from Aventis S.A., Frankfurt, Germany) methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include heparinoids, hirudin, recombinant hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist, antibody, and thrombin inhibitors such as ANGIOMAX™ (bivalirudin, Biogen, Inc., Cambridge, Mass.). Examples of cytostatic agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, N.J.), actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich 1001 West Saint Paul Avenue, Milwaukee, Wis. 53233; or COSMEGEN available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I1, actinomycin X1, and actinomycin C1. Other drugs include calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium.
Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, bioactive RGD, antibodies such as CD-34 antibody, abciximab (REOPRO), and progenitor cell capturing antibody, prohealing drugs that promotes controlled proliferation of muscle cells with a normal and physiologically benign composition and synthesis products, enzymes, antivirals, anticancer drugs, anticoagulant agents, free radical scavengers, steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agents, antibiotics, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), dexamethasone, clobetasol, aspirin, estradiol, tacrolimus, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), pimecrolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, ABT-578, progenitor cell capturing antibody, pro-drugs thereof, co-drugs thereof, and a combination thereof. The foregoing substances are listed by way of example and are not meant to be limiting. Other active agents which are currently available or that may be developed in the future are equally applicable.
The dosage or concentration of the bioactive agent required to inhibit or promote a favorable therapeutic effect should be less than the level at which the bioactive agent produces toxic effects and greater than the level at which non-therapeutic results are obtained. The dosage or concentration of the bioactive agent required to inhibit the desired cellular activity of the vascular region can depend upon factors such as the particular circumstances of the patient; the nature of the trauma; the nature of the therapy desired; the time over which the ingredient administered resides at the vascular site; and if other active agents are employed, the nature and type of the substance or combination of substances. Therapeutic effective dosages can be determined empirically, for example by infusing vessels from suitable animal model systems and using immunohistochemical, fluorescent or electron microscopy methods to detect the agent and its effects, or by conducting suitable in vitro studies. The bioactive compound can be incorporated into polymeric coating in a percent loading of between 0.01% and 70% by weight, more preferably between 5% and 50% by weight. Standard pharmacological test procedures to determine dosages are understood by one of ordinary skill in the art.
As used herein, an implantable device may be any suitable medical substrate that can be implanted in a human or veterinary patient. Examples of such implantable devices include self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation, Santa Clara, Calif.). The underlying structures of the device for the treatment of patent foramen ovale, aneurysm coils, and embolic protection devices can be of virtually any design. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Devices made from bioabsorbable or biostable polymers could also be used with the embodiments of the present invention. For example, the plasticizer could be added to alter the body of a stent made from a biodegradable or bioabsorbable polymer.
In accordance with embodiments of the invention, a coating of the various described embodiments can be formed on an implantable device or prosthesis, e.g., a stent. For coatings including one or more active agents, the agent will remain on the medical device such as a stent during delivery and expansion of the device, and released at a desired rate and for a predetermined duration of time at the site of implantation. Preferably, the medical device is a stent. A stent having the above-described coating is useful for a variety of medical procedures, including, by way of example, treatment of obstructions caused by tumors in bile ducts, esophagus, trachea/bronchi and other biological passageways. A stent having the above-described coating is particularly useful for treating occluded regions of blood vessels caused by abnormal or inappropriate migration and proliferation of smooth muscle cells, thrombosis, and restenosis. Stents may be placed in a wide array of blood vessels, both arteries and veins. Representative examples of sites include the iliac, renal, and coronary arteries.
For implantation of a stent, an angiogram is first performed to determine the appropriate positioning for stent therapy. An angiogram is typically accomplished by injecting a radiopaque contrasting agent through a catheter inserted into an artery or vein as an x-ray is taken. A guidewire is then advanced through the lesion or proposed site of treatment. Over the guidewire is passed a delivery catheter which allows a stent in its collapsed configuration to be inserted into the passageway. The delivery catheter is inserted either percutaneously or by surgery into the femoral artery, brachial artery, femoral vein, or brachial vein, and advanced into the appropriate blood vessel by steering the catheter through the vascular system under fluoroscopic guidance. A stent having the above-described coating may then be expanded at the desired area of treatment. A post-insertion angiogram may also be utilized to confirm appropriate positioning.
The embodiments of the present invention will be illustrated by the following set forth examples. All parameters and data are not to be construed to unduly limit the scope of the embodiments of the invention.
In this example, a conventional ring opening polymerization of D,L-lactide is performed using stannous octoate as a catalyst, and 1-hexanol as an initiator. A 2-necked, 100 ml flask equipped with stopcock, septum and stirbar can be flame dried under vacuum, and purged with argon. Inside an argon filled glove box, D,L-lactide (50 gm, 0.347 mol) is placed with stannous octoate (1.41 gm, 0.0347 mol). The reaction mixture can be heated in an oil bath with stirring to 140° C. At time zero, 1-hexanol is added (35.4 gm, 0.347 mol) and the reaction allowed to proceed for 2 hours. The reaction mixture is poured into 500 ml of methanol, the precipitated oil isolated, and dried under vacuum.
A first composition can be prepared by mixing the following components:
The first composition can be applied onto the surface of bare 12 mm small VISION stent (available from Guidant Corporation). The coating can be sprayed and dried to form a primer layer. A spray coater can be used having a 0.014 round nozzle maintained at ambient temperature with a feed pressure 2.5 psi (0.17 atm) and an atomization pressure of about 15 psi (1.02 atm). About 20 μg of the coating can be applied at per one spray pass. Between the spray passes the stent can be dried for about 10 seconds in a flowing air stream at about 50° C. About 100 μg of wet coating can be applied. The stents can be baked at about 80° C. for about one hour, yielding a primer layer composed of approximately 80 μg of poly(D,L-lactide).
A second composition is prepared by mixing the following components:
The composition is applied onto the surface of the stent. Coating is sprayed and dried to form a drug reservoir layer. A spray coater is used having a 0.014 round nozzle maintained at ambient temperature with a feed pressure 2.5 psi (0.17 atm) and an atomization pressure of about 15 psi (1.02 atm). Coating is applied at 20 μg per pass, in between which the stent is dried for 10 seconds in a flowing air stream at 50° C. Approximately 500 μg of wet coating is applied. The stents are baked at 60° C. for one hour, yielding a drug reservoir layer composed of approximately 450 μg of coating.
A layer of Parylene™ C, 5 microns thick, is applied to all surfaces of a bare 12 mm small VISION stent (available from Guidant Corporation), by thermal vapor deposition.
A composition is prepared by mixing the following components:
The composition is applied onto only the abluminal surfaces of the VISION stent. Coating is applied using an inkjet microdispenser with CNC controller and imaging system to position the stent under the dispensing nozzle. Six passes are applied with 5 minutes of air drying between each pass. Approximately 300 μg of wet coating is applied. The stents are baked at 60° C. for one hour, yielding a drug reservoir layer composed of approximately 270 μg of coating.
While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.
This application is a continuation of U.S. application Ser. No. 12/475,296, filed on May 29, 2009, published as US 2009-0238854 A1 on Sep. 24, 2009, and issuing as U.S. Pat. No. 8,980,300 B2 on Mar. 17, 2015, which is a continuation application of U.S. application Ser. No. 10/913,607, filed on Aug. 5, 2004, now abandoned; the teachings of both of which are incorporated herein in their entirety by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2158107 | Gurruthers et al. | May 1939 | A |
| 2260295 | Gurruthers et al. | Oct 1941 | A |
| 2350388 | Claborn | Jun 1944 | A |
| 2371281 | Claborn | Mar 1945 | A |
| 2917410 | Vitalis | Dec 1959 | A |
| 4273137 | Pravoverov et al. | Jun 1981 | A |
| 4539981 | Tunc | Sep 1985 | A |
| 4645503 | Lin et al. | Feb 1987 | A |
| 4655771 | Wallsten | Apr 1987 | A |
| 4979822 | Sommer | Dec 1990 | A |
| 5085629 | Goldberg et al. | Feb 1992 | A |
| 5304121 | Sahatjian | Apr 1994 | A |
| 5342621 | Eury et al. | Aug 1994 | A |
| 5433751 | Christel et al. | Jul 1995 | A |
| 5447724 | Helmus et al. | Sep 1995 | A |
| 5464650 | Berg et al. | Nov 1995 | A |
| 5468253 | Bezwada et al. | Nov 1995 | A |
| 5487897 | Polson et al. | Jan 1996 | A |
| 5496359 | Davidson | Mar 1996 | A |
| 5508036 | Bakker et al. | Apr 1996 | A |
| 5522895 | Mikos | Jun 1996 | A |
| 5539081 | Gruber et al. | Jul 1996 | A |
| 5581387 | Cahill | Dec 1996 | A |
| 5624411 | Tuch | Apr 1997 | A |
| 5637113 | Tartaglia et al. | Jun 1997 | A |
| 5649977 | Campbell | Jul 1997 | A |
| 5665428 | Cha et al. | Sep 1997 | A |
| 5670161 | Healy et al. | Sep 1997 | A |
| 5674192 | Sahatjian et al. | Oct 1997 | A |
| 5674286 | D'Alessio et al. | Oct 1997 | A |
| 5700901 | Hurst et al. | Dec 1997 | A |
| 5702717 | Cha et al. | Dec 1997 | A |
| 5741329 | Agrawal et al. | Apr 1998 | A |
| 5747637 | Shinoda et al. | May 1998 | A |
| 5824048 | Tuch | Oct 1998 | A |
| 5824049 | Ragheb et al. | Oct 1998 | A |
| 5824059 | Wijay | Oct 1998 | A |
| 5834582 | Sinclair et al. | Nov 1998 | A |
| 5955096 | Santos et al. | Sep 1999 | A |
| 5980564 | Stinson | Nov 1999 | A |
| 6077989 | Kandel et al. | Jun 2000 | A |
| 6121410 | Gruber et al. | Sep 2000 | A |
| 6143863 | Gruber et al. | Nov 2000 | A |
| 6153252 | Hossainy et al. | Nov 2000 | A |
| 6174329 | Callol et al. | Jan 2001 | B1 |
| 6214901 | Chudzik et al. | Apr 2001 | B1 |
| 6224622 | Kotzev | May 2001 | B1 |
| 6235061 | Laurencin et al. | May 2001 | B1 |
| 6240616 | Yan | Jun 2001 | B1 |
| 6241771 | Gresser et al. | Jun 2001 | B1 |
| 6251136 | Guruqaiya et al. | Jun 2001 | B1 |
| 6335029 | Kamath et al. | Jan 2002 | B1 |
| 6368658 | Schwarz et al. | Apr 2002 | B1 |
| 6747121 | Gogolewski et al. | Jun 2004 | B2 |
| 6780424 | Claude | Aug 2004 | B2 |
| 6840961 | Tofighi et al. | Jan 2005 | B2 |
| 6916788 | Seo et al. | Jul 2005 | B2 |
| 6939376 | Schulze et al. | Sep 2005 | B2 |
| 7018401 | Hyodoh et al. | Mar 2006 | B1 |
| 7153520 | Seo et al. | Dec 2006 | B2 |
| 7160592 | Rypacek et al. | Jan 2007 | B2 |
| 7202325 | Hossainy | Apr 2007 | B2 |
| 7244443 | Pacetti | Jul 2007 | B2 |
| 7247313 | Roorda et al. | Jul 2007 | B2 |
| 7255891 | Pacetti | Aug 2007 | B1 |
| 7261946 | Claude | Aug 2007 | B2 |
| 7288609 | Pacetti | Oct 2007 | B1 |
| 7291166 | Cheng et al. | Nov 2007 | B2 |
| 7294329 | Ding | Nov 2007 | B1 |
| 7311980 | Hossainy et al. | Dec 2007 | B1 |
| 7807211 | Hossainy et al. | Oct 2010 | B2 |
| 7820732 | Hossainy et al. | Oct 2010 | B2 |
| 8551512 | Hossainy et al. | Oct 2013 | B2 |
| 8980300 | Pacetti et al. | Mar 2015 | B2 |
| 20010007083 | Roorda | Jul 2001 | A1 |
| 20020016625 | Falotico et al. | Feb 2002 | A1 |
| 20020041898 | Unger et al. | Apr 2002 | A1 |
| 20020107330 | Pinchuk et al. | Aug 2002 | A1 |
| 20030059454 | Barry et al. | Mar 2003 | A1 |
| 20030069629 | Jadhav et al. | Apr 2003 | A1 |
| 20030072868 | Harish et al. | Apr 2003 | A1 |
| 20030073961 | Happ | Apr 2003 | A1 |
| 20030082368 | Reuter et al. | May 2003 | A1 |
| 20030083646 | Sirhan et al. | May 2003 | A1 |
| 20030083740 | Pathak | May 2003 | A1 |
| 20030139567 | Kim et al. | Jul 2003 | A1 |
| 20030158517 | Kokish | Aug 2003 | A1 |
| 20030190406 | Hossainy | Oct 2003 | A1 |
| 20030199993 | Gellman et al. | Oct 2003 | A1 |
| 20030216307 | Kohn et al. | Nov 2003 | A1 |
| 20030236320 | Martin et al. | Dec 2003 | A1 |
| 20040001872 | Shih et al. | Jan 2004 | A1 |
| 20040009226 | McHugh et al. | Jan 2004 | A1 |
| 20040052858 | Wu et al. | Mar 2004 | A1 |
| 20040060508 | Pacetti | Apr 2004 | A1 |
| 20040062853 | Pacetti et al. | Apr 2004 | A1 |
| 20040106987 | Palasis et al. | Jun 2004 | A1 |
| 20040138333 | Kim et al. | Jul 2004 | A1 |
| 20040148002 | Cheng et al. | Jul 2004 | A1 |
| 20040162609 | Hossainy et al. | Aug 2004 | A1 |
| 20040180132 | Pacetti | Sep 2004 | A1 |
| 20040191405 | Kerrigan | Sep 2004 | A1 |
| 20040199241 | Gravett et al. | Oct 2004 | A1 |
| 20040220656 | Epstein et al. | Nov 2004 | A1 |
| 20040253203 | Hossainy et al. | Dec 2004 | A1 |
| 20050021127 | Kawula | Jan 2005 | A1 |
| 20050074544 | Pacetti et al. | Apr 2005 | A1 |
| 20050112170 | Hossainy et al. | May 2005 | A1 |
| 20050112172 | Pacetti | May 2005 | A1 |
| 20050118344 | Pacetti | Jun 2005 | A1 |
| 20050214339 | Tang et al. | Sep 2005 | A1 |
| 20050226991 | Hossainy et al. | Oct 2005 | A1 |
| 20050233062 | Hossainy et al. | Oct 2005 | A1 |
| 20050265960 | Pacetti et al. | Dec 2005 | A1 |
| 20050271700 | Desnoyer et al. | Dec 2005 | A1 |
| 20050277577 | Hunter et al. | Dec 2005 | A1 |
| 20050287184 | Hossainy et al. | Dec 2005 | A1 |
| 20060002968 | Stewart et al. | Jan 2006 | A1 |
| 20060034888 | Pacetti et al. | Feb 2006 | A1 |
| 20060035854 | Goldstein et al. | Feb 2006 | A1 |
| 20060041102 | Hossainy et al. | Feb 2006 | A1 |
| 20060047095 | Pacetti et al. | Mar 2006 | A1 |
| 20060062821 | Simhambhatla et al. | Mar 2006 | A1 |
| 20060088571 | Chen et al. | Apr 2006 | A1 |
| 20060089485 | DesNoyer et al. | Apr 2006 | A1 |
| 20060093771 | Rypacek et al. | May 2006 | A1 |
| 20060095122 | Pacetti | May 2006 | A1 |
| 20060115449 | Pacetti | Jun 2006 | A1 |
| 20060171985 | Richard et al. | Aug 2006 | A1 |
| 20060246108 | Pacetti et al. | Nov 2006 | A1 |
| 20070032853 | Hossainy et al. | Feb 2007 | A1 |
| Number | Date | Country |
|---|---|---|
| 0761712 | Mar 1997 | EP |
| 0 950 386 | Oct 1999 | EP |
| 07163654 | Jun 1995 | JP |
| 09-511666 | Nov 1997 | JP |
| 09-511741 | Nov 1997 | JP |
| 2003-532489 | Nov 2003 | JP |
| WO 9527481 | Oct 1995 | WO |
| WO 9528124 | Oct 1995 | WO |
| WO 0185061 | Nov 2001 | WO |
| WO 0218477 | Mar 2002 | WO |
| WO 03082368 | Oct 2003 | WO |
| WO 2004108111 | Dec 2004 | WO |
| WO 2005053571 | Jun 2005 | WO |
| WO 0145763 | Jun 2011 | WO |
| WO 0187368 | Nov 2011 | WO |
| Entry |
|---|
| “Inherent Viscosity vs Molecular Weight,” LACTEL Absorbable Polymers, http://absorbables.com/technical/inherent—viscosity.html, Nov. 4, 2013, pp. 1-3. |
| Cai et al. “Synthesis and Characterization of Polycaprolactone (B)-Poly(lactide-co-glycolide) (A) ABA Block Copolymer,” Polym. Adv. Technol., 2000, vol. 11, pp. 159-166. |
| Filachione et al., “Lactic Acid Derivatives as Plasticizers Esters of Polymeric Lactic Acid,” Bur. Agric. and Ind. Chem., 1951 pp. 1-19. |
| Handbook of Pharmaceutical Excipients, Am. Pharm. Assoc. pp. 209-213 (polyethylene glycol) (1986). |
| International Preliminary Report mailed Jan. 5, 2010, for PCT Application No. PCT/US2008/064585, filed May 22, 2008, 6 pp. |
| Jain R., The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices (2000) Biomaterials 21:2475-2490. |
| Joziasse et al. “Rubber toughened linear and star-shaped poly(d,l-lactide-co-glycolide): synthesis, properties and in vitro degradation,” Polymer, 1998, vol. 39, No. 2, pp. 467-474. |
| Kricheldorf, et al. “A-B-A-Triblock and mutiblock copolyesters prepared from ε-caprolactone, glycolide and L-lactide by means of bismuth subsalicylate,” Polymers 46, 2005, pp. 3248-3256. |
| Lactel, Absorbable Polymers Inherent Viscosity vs. Molecular Weight, downloaded from: www.absorbables.com/inherentviscosity.htm, Jun. 15, 2010, 2 pp. |
| Merriam-Webster Online Dictionary: “prodrug” (http://www.merriam-webster.com/medical/prodrug), 2010, pp. 1-2. |
| Windholz et al. Ed. The Merck Index “Lactic/Lactic Acid,” Merck & Co., 1976, pp. 1-2. |
| Rodriguez, Ferdinanad, Principles of Polymer Systems, Fourth edition, Taylor&Francis, 1996, Title page and p. 1, 3 pages. |
| Fried, Joel R., Polymer Science and Technology, Prentice Hall, Englewood Cliffs, New Jersey, 1995, Title page and pp. 1, 2, and 4, 5, pages. |
| “Oligomer,” http://www.yourdictionary.com/oligomer, Jul. 14, 2014, 2pp. |
| “Polymer,” http://www.thefreedictionary.com/polymer, Jul. 14, 2014, pp. 1-3. |
| “Oligomer,” http://www.thefreedictionary.com/oligomer, Jul. 14, 2014, pp. 1-2. |
| Scapin et al., “Use of triethylcitrate plasticizer in the production of poly-L-lactic acid implants with different degradation times,” J. Mater. Sci.: Mater. In Med. 14:635-640 (2003). |
| Final Office Action in U.S. Appl. No. 10/913,607, mailed on Jan. 29, 2009; 11 pages. |
| Amendment in U.S. Appl. No. 10/913,607, filed Aug. 15, 2008; 15 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20150150989 A1 | Jun 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12475296 | May 2009 | US |
| Child | 14621301 | US | |
| Parent | 10913607 | Aug 2004 | US |
| Child | 12475296 | US |
